For some reason I feel like the primary partner will be non-traditional. I am thinking with the broadened type 2 studies and all the discussion regarding the use of Afrezza in early onset diabetes as the first line of defense in pre-diabetes, we shouldn't think diabetes drug marketers. I think it will be either somebody with a huge presence in the family practioner office (J&J) or somebody who markets supplies and pumps (Medtronic).

All IMHO.

Swing